Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 145

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 145
---
 federal financial supervisory authority, the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), in the coming weeks. No later than ten business days prior to expiration of the deadline for shareholders to accept the offer, we intend to apply to delist the Biotest AG shares and remove such shares from trading on the Frankfurt Securities Exchange.
​

94

Changes in Board of Directors 
On February 25, 2025, Mr. Thomas Glanzmann, our non-executive Chairperson of the Board of Directors, announced that he will retire from the Board following our general shareholders’ meeting in 2025, expected to occur in June. Mr. Glanzmann will be replaced by independent Board member Ms. Anne-Catherine Berner as non-executive Chairperson. With the appointment of an independent Chairperson, the position of independent lead director will no longer be mandatory under Spanish law. Our Board will not propose the replacement of such vacancy and will propose to reduce the total number of Board members to 12 following the general shareholders’ meeting of 2025.
Acquisition of Plasma Collection Centers From ImmunoTek
On April 1, 2024, through our subsidiary Grifols Bio North America, LLC (“GNBA”), we acquired from ImmunoTek seven plasma collection centers located in the United States for $134.9 million. On July 1, 2024, GNBA acquired an additional seven U.S. plasma collection centers from ImmunoTek for $130.1 million. These transactions were carried out pursuant to the collaboration agreement entered into with ImmunoTek in 2021, amended in 2023 and 2024, to arrange for the construction, licensing and commissioning of 28 plasma collection centers in the U.S. Pursuant to this agreement, we formed ITK JV, a joint operation company through which we initially held a 75% interest in each of the 28 plasma collection centers, while ImmunoTek held the remaining 25%. See Item 4 of this Part I, “Information on the Company—B. Business Overview—Raw Materials” and Notes 3, 10 and 34 to our audited consolidated financial statements included in this annual report. 
As scheduled under the collaboration agreement, effective as of January 2, 2025, we purchased eight plasma collection centers for a total amount of $158.9 million. Although the acquisition of the last six plasma collection centers was scheduled for January 2026, we amended the